Skip to main content Back to Top
Advertisement

3/23/2018

Disopyramide Phosphate Controlled-Release Capsules

Products Affected - Description

    • Norpace CR oral extended release capsule, Pfizer, 100 mg, bottle, 500 count, NDC 00025-2732-51
    • Norpace CR oral extended release capsule, Pfizer, 150 mg, bottle, 500 count, NDC 00025-2742-51

Reason for the Shortage

    • Pfizer had disopyramide controlled-release capsules on shortage due to manufacturing delays. The 500 count sizes were discontinued in March 2018.

Available Products

    • Norpace CR oral extended release capsule, Pfizer, 100 mg, bottle, 100 count, NDC 00025-2732-31
    • Norpace CR oral extended release capsule, Pfizer, 150 mg, bottle, 100 count, NDC 00025-2742-31

Estimated Resupply Dates

    • Pfizer has Norpace CR 100 mg capsules in 100 count and 150 mg capsules in 100 count available.

Updated

Updated March 23, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 9, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. Copyright 2018, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins